New Stock News | Yimufeng Biotechnology has submitted another application to the Hong Kong Stock Exchange. The core product IMC002 has submitted an application for investigational new drug status to the National Medical Products Administration.

According to Hong Kong Stock Exchange disclosure on August 18, Shenzhen Yimu Peak Biotechnology Co., Ltd.-B (hereinafter referred to as "Yimu Peak Biotechnology") has submitted a new application for the Main Board of the Hong Kong Stock Exchange, with Huatai International as the sole sponsor. Company Profile According to the prospectus, the company was founded in 2020 and is an innovative cell therapy company focused on discovering, developing, manufacturing, and commercializing Chimeric Antigen Receptor (CAR) T-cell therapies. It utilizes a dual-engine approach that integrates both in vivo and ex vivo CAR-T cell therapies to treat solid tumors, hematological malignancies, and autoimmune diseases. The company has a core product (IMC002), a self-developed, potential best-in-class anti-Claudin18.2 (CLDN18.2) CAR-T cell therapy candidate. The company is currently conducting a registrational Phase III clinical trial for IMC002 in China for the treatment of advanced gastric adenocarcinoma/gastroesophageal junction (GC/GEJ) cancer, and has submitted an investigational new drug application (IND) to the National Medical Products Administration in June 2026 for IMC002 as a first-line treatment for pancreatic cancer as an additional indication. In addition to IMC002, the company has eight other self-developed cell therapy candidates in its pipeline, including (1) IMC001, a potential first-in-class clinical-stage (Phase I/IIa) anti-epithelial cell adhesion molecule (EpCAM) CAR-T cell therapy candidate for the treatment of EpCAM-positive solid tumors; (2) in vivo CAR-T cell therapy candidates for the treatment of hematological malignancies and autoimmune diseases (IMV101) and for the treatment of hematological malignancies (IMV102), which are currently in investigator-initiated trials (IIT); (3) an in vivo CAR-T cell therapy candidate for solid tumors (IMV103), which has received ethics committee approval for IIT and is expected to enter the IND application stage in the first half of 2027; (4) a targeted CD19/CD20 bispecific in vivo CAR-T cell therapy candidate (IMV104) for the treatment of B-cell diseases; (5) a "synthetic NKG2D receptor" CAR-T cell therapy for the treatment of CLDN18.2-positive solid tumors; and (6) two additional CAR-T cell therapy candidates that are in preclinical development. Financial Information Revenue For the fiscal years 2024, 2025, and the six months ending June 30, 2026, the company reported other income and revenue of approximately RMB 3.36 million, RMB 4.019 million, and RMB 6.632 million, respectively. Loss For the fiscal years 2024, 2025, and the six months ending June 30, 2026, the company's losses were approximately RMB 71.312 million, RMB 115 million, and RMB 109 million, respectively. Industry Overview Cancer is one of the leading causes of death globally, and it is expected that the incidence of cancer will continue to rise due to aging populations, lifestyle-related risk factors, and population growth. By 2025, there will be an estimated 21.9 million new cancer cases globally, with around 11 million cancer deaths, highlighting the high incidence and heavy mortality burden of the disease. In 2023, cancer accounted for a total of 271 million disability-adjusted life years, 97% of which were due to years of life lost, reflecting the global cancer mortality burden. In terms of global incidence, solid tumors account for the vast majority of cancer cases, expected to represent about 90% of all new cancer cases globally by 2025, and to remain at similar levels by 2035. The number of new cases of solid tumors globally is projected to increase from 20.5 million in 2025 to 25.3 million in 2035. Meanwhile, hematological malignancies also constitute an important category of malignant diseases. In 2025, the five most common types of solid tumors globally will be lung cancer, breast cancer, colorectal cancer, prostate cancer, and gastric cancer. Gastric cancer will have approximately 1 million new cases diagnosed globally each year, ranking among the top five in the number of new diagnoses for solid tumor indications. Cancer treatment has undergone a long historical development process and will continue to evolve in the future. Existing cancer treatment methods include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and cellular and gene therapy. These methods collectively encompass strategies for curing, controlling, and alleviating diseases, reflecting a shift from broad-spectrum cytotoxic therapies to more precise, biologically-driven interventions. Immuno-oncology is an emerging pillar of cancer treatment. From 2025 to 2035, immuno-oncology is expected to achieve the highest compound annual growth rate among major cancer treatment modalities, reflecting its rapid clinical adoption and strategic importance in the field of tumor treatment. This process can be achieved by activating the immune system to attack cancer cells or supplementing components of the immune system. According to market standards, immuno-oncology therapies are primarily divided into cell immunotherapy (such as CAR-T and TCR-T), cytokines, immune checkpoint monoclonal antibodies, oncolytic viruses, T-cell engagers (TCE), and cancer vaccines. These treatment modalities aim to modulate, activate, or redirect T-cell function, thereby enhancing anti-tumor immunity. Among these strategies, T-cells are the primary effector cells for adaptive anti-tumor immunity. Specifically, genetically modified T-cell therapies (such as CAR-T cell therapy) can directly modify a patient's T-cells to equip them with tumor-specific recognition capabilities and effective cytotoxic activity, making CAR-T one of the most mature and clinically validated treatment modalities in the field of immuno-oncology. The following chart shows the historical size of the global and Chinese CAR-T cell therapy market from 2020 to 2025, as well as forecasts for the size from 2026 to 2035: Board Information After compilation, the board will consist of nine directors, including three executive directors, three non-executive directors, and three independent non-executive directors. The board is responsible for business management and operations, and has general authority. Equity Structure As of the last practicable date (August 11, 2026), Dr. Sun has the right to control approximately 24.98% of the voting rights attached to the total issued share capital, of which approximately 4.95% of the total issued share capital is directly held by him, and approximately 20.03% of the total issued share capital is indirectly controlled by him through the general partners of Shanghai Haiyi, Shanghai Yizhong, and Shanghai Yimu, which respectively hold 12.93%, 5.27%, and 1.83% of the total issued share capital. In addition, Dr. Sun has the right to control the composition of the majority of the board members according to the shareholders' agreement prior to compiling the board. Therefore, Dr. Sun and his controlled entities are considered the controlling shareholders before compilation. Intermediary Team Sole Sponsor: Huatai Financial Holdings (Hong Kong) Limited; Legal Advisors: Fangda Partners, Zhonglun W&D Law Firm; Legal Advisors to the Sole Sponsor: King & Wood Mallesons, Jingtian Gongcheng Law Firm; Auditors and Reporting Accountants: Ernst & Young; Industry Advisors: Frost & Sullivan (Beijing) Consulting Co., Ltd. Shanghai Branch; Compliance Advisor: Hongbo Capital Limited.